Alexion to Pay as Much as $1.08 Billion to Buy Enobia Pharma

Alexion Pharmaceuticals Inc., the maker of a drug for a rare blood disease, agreed to acquire closely held Enobia Pharma Corp. for as much as $1.08 billion, adding experimental treatments for genetic metabolic disorders.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.